SANUWAVE Health reports record Q1 2026 revenues of $9.6M, with strategic growth initiatives and a positive outlook for future performance.

Key Takeaways

• Record Q1 Revenues: SANUWAVE reported revenues of $9.6 million, marking a 3% increase year-over-year and surpassing the previous record.
• Increased Unit Sales: The company sold 97 systems in Q1 2026, bringing total active systems to 1,382, a 90 unit increase compared to prior periods.
• Improved EBITDA: Adjusted EBITDA was positive $1.1 million, a decline from $2.3 million in Q1 2025, due to investments in R&D and commercialization.
• Positive Outlook: Management anticipates 10-15% growth for Q2 2026 and maintains annual guidance of $51-55 million.
• Operational Changes: The company is entering into voluntary disclosure agreements to address sales tax issues, which could mitigate potential liabilities.

Financial Performance

SANUWAVE Health, Inc. delivered an impressive financial performance in the first quarter of 2026. The company achieved record revenues of $9.6 million, reflecting a 3% increase from $9.3 million reported for the same period last year. This growth, while on the lower end of the company's guidance of 3-10%, indicates a recovery trajectory in the advanced wound care market after a challenging start to the year.

The gross margin for the quarter was 77.3%, a slight decrease of 177 basis points year-over-year, primarily due to wholesale pricing shifts impacting the Altrum systems and applicators sold through resellers. Operating loss for Q1 totaled $1.1 million, compared to an operating income of $0.6 million in Q1 2025, driven by increased operating expenses and investments in product development.

Despite these challenges, the net loss improved significantly to $1.4 million, a reduction of $4.7 million compared to the same quarter last year, largely due to a non-cash loss that did not recur this quarter. The company ended the quarter with total current assets of $24 million, and cash and cash equivalents stood at $10.8 million.

Strategic Initiatives

The company is focusing on several strategic initiatives to enhance its market position. Notably, SANUWAVE sold 97 systems in Q1, which contributed to a total of 1,382 active systems in operation, an increase from 1,292 at the end of 2025. This positive trend in unit sales is a strong indicator of market recovery after a period of stagnation due to uncertainties surrounding CMS pricing policies.

Management has also noted a shift in focus towards partnerships with long-term care facilities and hospitals, as well as an expansion into mobile wound care. Despite some misconceptions about the viability of mobile wound care, the company asserts that the demand remains strong, driven by the need for effective wound treatment in underserved communities.

Furthermore, SANUWAVE is making significant strides in addressing its sales tax compliance issues through voluntary disclosure agreements with states, which should limit potential liabilities and provide clarity moving forward.

Future Outlook

Looking ahead, SANUWAVE's management expressed optimism about the company's growth trajectory. For Q2 2026, they anticipate 10-15% year-over-year growth, projecting revenues between $11.1 million and $11.6 million. This growth is supported by increasing engagement from large healthcare systems and a favorable seasonal trend that historically sees a 48% increase in the second half of the year compared to the first half.

The company is also actively working on research and development initiatives to enhance the Ultramist product line, with expectations of new advancements and clinical evidence supporting its efficacy. Management is confident that as the market stabilizes and capital budgets thaw, sales cycles will shorten, leading to improved financial performance in the latter half of the year.

Overall, SANUWAVE is well-positioned to capitalize on its strategic initiatives and market dynamics, supported by a solid foundation of operational discipline and a resilient product offering.

In conclusion, SANUWAVE Health, Inc. has shown resilience during a challenging first quarter, achieving record revenues and maintaining a positive outlook for future growth. The company's focus on strategic partnerships and product development, coupled with an improving market environment, suggests a strong potential for sustained profitability and success in the advanced wound care sector.

This analysis is based on public earnings call materials and is not investment advice.